HCPCS G9841: Ras (KRAS and NRAS) Mutation Testing Not Performed Before Anti-EGFR Therapy - OpenPayer

Summary & Overview

HCPCS G9841: Ras (KRAS and NRAS) Mutation Testing Not Performed Before Anti-EGFR Therapy

HCPCS Level II code G9841 indicates that Ras (KRAS and NRAS) gene mutation testing was not performed prior to initiation of anti-EGFR monoclonal antibody therapy. This documentation-only code matters because RAS mutation status is a key biomarker that guides the use of anti-EGFR therapies in oncology; absence of testing can affect treatment selection and downstream quality reporting. Nationally, the code supports administrative tracking of cases where guideline-recommended molecular testing was not completed before therapy.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise overview of clinical context for the code, common modifiers and administrative considerations, payer coverage patterns, and how the code is used in claims and quality measurement. The report outlines benchmarks for use where available and notes when specific data elements are not provided.

The publication provides practical clarity on the code’s purpose, identifies typical service settings, and summarizes implications for coding, billing, and care documentation. It is intended for health plan analysts, coding professionals, oncology clinic administrators, and policy staff seeking a clear national-level description of G9841 and its role in documenting lack of pre-treatment RAS testing.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9841HCPCS Level IIRAS testinganti-EGFR monoclonal antibodyoncologymolecular diagnosticsclinical documentationcodingquality measurement

Billing Code Overview

HCPCS Level II code G9841 indicates that Ras (KRAS and NRAS) gene mutation testing was not performed before initiation of anti-EGFR monoclonal antibody therapy. This code documents the absence of pre-treatment molecular testing for RAS mutations when anti-EGFR monoclonal antibody treatment is begun.

Service type: Molecular diagnostic documentation (absence of testing) related to targeted oncology therapy
Typical site of service: Oncology clinic or hospital outpatient setting where anti-EGFR monoclonal antibody therapy is initiated

Clinical & Coding Specifications

Clinical Context

A typical patient scenario involves an adult with metastatic colorectal carcinoma being considered for anti-EGFR monoclonal antibody therapy (for example, cetuximab or panitumumab). Before initiating therapy, current guidelines require determination of RAS mutational status because activating mutations in KRAS or NRAS predict lack of response to anti-EGFR agents. The clinical workflow begins with the oncology clinic identifying the need for targeted therapy after pathologic confirmation of colorectal adenocarcinoma and staging imaging that demonstrates metastatic disease. A tissue specimen (recent primary tumor resection or metastatic biopsy) is sent to a molecular pathology laboratory for RAS gene mutation testing. If testing was not performed prior to ordering anti-EGFR monoclonal antibody therapy, the billing code G9841 documents that RAS (KRAS and NRAS) gene mutation testing was not performed before initiation of anti-EGFR monoclonal antibody therapy. Typical site of service is an outpatient oncology clinic or hospital outpatient infusion center where systemic therapy is administered. Typical modifiers used could indicate professional/technical components, unusual services, or situations such as patient refusal or specimen issues. The typical patient is an adult with metastatic colorectal cancer being evaluated for first- or later-line anti-EGFR monoclonal antibody therapy where RAS testing is absent or unavailable prior to therapy start.

Coding Specifications

Modifier	Description	When to Use

HCPCS G2155: Documentation of Contraindication to Tdap/Td Vaccination

HCPCS-G0250-HOME-INR-TESTING-REVIEW-MANAGEMENT

HCPCS G0250: Physician Review and Management of Home INR Testing

HCPCS-G9628-BOWEL-INJURY-POSTOPERATIVE-UP-TO-30-DAYS

HCPCS G9628: Bowel Injury at Time of Surgery or Within 30 Days

HCPCS-G8662-LOW-BACK-IMPAIRMENT-RESIDUAL-SCORE-NOT-MEASURED

HCPCS G8662: Residual Low Back Impairment Score Not Measured

HCPCS-G8655-LOWER-LEG-FOOT-ANKLE-IMPAIRMENT-SCORE

HCPCS G8655: Residual Lower Leg, Foot, or Ankle Impairment Score

HCPCS-G9413-CIED-INFECTION-DEVICE-REMOVAL-OR-REVISION

HCPCS G9413: CIED Infection Requiring Device Removal or Surgical Revision

HCPCS-G0122-BARIUM-ENEMA-COLORECTAL-CANCER-SCREENING

HCPCS G0122: Colorectal Cancer Screening, Barium Enema

HCPCS-G1022-CLINICAL-DECISION-SUPPORT-INTERMOUNTAIN

HCPCS G1022: Intermountain Clinical Decision Support Mechanism

HCPCS-G9188-BETA-BLOCKER-THERAPY-NOT-PRESCRIBED

HCPCS G9188: Beta-Blocker Therapy Not Prescribed, Reason Not Given

HCPCS-G2201-DOCUMENTATION-OF-MEDICAL-REASON-FOR-NOT-PROVIDING-BRIEF-COUNSELING

HCPCS G2201: Documentation of Medical Reason for Not Providing Brief Counseling

Showing 1–10 of 1996

`22`	Increased procedural services	Use when additional documentation supports substantially greater effort for services related to ordering or documenting molecular testing status when unusually complex counseling or documentation is required prior to therapy.
`23`	Unusual anesthesia	Not typically applicable to this code; reserved for cases where anesthesia was required for a biopsy that influenced testing availability.
`52`	Reduced services	Use when testing was partially completed but not finalized before therapy initiation.
`53`	Discontinued procedure	Use if a planned biopsy for molecular testing was attempted but aborted prior to obtaining adequate tissue.
`54`	Surgical care only	Use when a surgeon provided only the surgical portion (biopsy/resection) and molecular testing was handled elsewhere.
`55`	Postoperative management only	Use when reporting only postoperative management related to obtaining tissue for testing.
`56`	Preoperative management only	Use when only preoperative management led to inability to obtain testing prior to therapy.
`62`	Two surgeons	Use if two surgeons were required for obtaining tissue for molecular testing impacting timing.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist service	Use when an advanced practitioner provided the service related to counseling or documentation about missing RAS testing.
`CQ`	Service furnished by a clinical staff for a clinical trial research element	Use when missing testing relates to a patient enrolled in a clinical trial and the service is trial-related.
`FX`	One physician absent, replaced by another physician	Use when primary physician unavailable and replacement affected timing of testing.
`FY`	Split/shared E/M	Use when service documenting missing testing is split/shared between hospital-employed physician and other practitioner.
`QK`	Medical direction of 2–4 technicians	Use in laboratory settings when a physician directs multiple lab technicians responsible for testing, but testing not performed before therapy.
`QX`	Service furnished under a physician's supervision by a non-physician practitioner	Use when a non-physician practitioner supervised the process that led to initiation without prior testing.

Taxonomy Code	Specialty	Notes
`207RC0000X`	Medical Oncology	Medical oncologists order systemic anti-EGFR agents and document testing status.
`208000000X`	Pathology	Pathologists direct molecular testing and interpret RAS mutation assays.
`364S00000X`	Hematology/Oncology	Hematologist-oncologists involved in systemic therapy decisions for colorectal cancer.
`207Q00000X`	Surgical Oncology	Surgeons obtain tissue biopsies or resections used for molecular testing.
`363L00000X`	Nurse Practitioner	Advanced practice providers coordinate testing, counseling, and documentation.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C18.9`	Malignant neoplasm of colon, unspecified	Represents colorectal primary tumor where RAS testing guides anti-EGFR therapy decisions.
`C19`	Malignant neoplasm of rectosigmoid junction	Colorectal cancer subsite commonly requiring RAS testing for targeted therapy selection.
`C20`	Malignant neoplasm of rectum	Rectal primary tumor in metastatic disease where RAS status impacts use of anti-EGFR agents.
`C78.7`	Secondary malignant neoplasm of liver and intrahepatic bile duct	Common metastatic site prompting systemic therapy and need for RAS testing.
`C79.51`	Secondary malignant neoplasm of bone	Metastatic disease where systemic therapy selection depends on RAS mutation status.
`Z85.038`	Personal history of malignant neoplasm of large intestine	History code used in surveillance contexts where reassessment of molecular status may be relevant.
`R21`	Rash and other nonspecific skin eruption	Included when adverse skin reactions occur during anti-EGFR therapy; documents therapy-related events when RAS testing was not performed prior to initiation.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81210`	KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) gene analysis; targeted sequence analysis of codons 12 and 13	Commonly performed molecular test that assesses KRAS hotspot mutations prior to anti-EGFR therapy; often ordered when full RAS testing is incomplete.
`81479`	Unlisted molecular pathology procedure	Used for reporting non-listed or novel RAS testing methods when no specific CPT exists; may be used in complex or nonstandard assays related to RAS analysis.
`88342`	Immunohistochemistry, per specimen; initial single antibody stain	Performed on tissue to help characterize tumor and may be part of the diagnostic workup before molecular testing.
`88377`	Consultation and interpretation of molecular pathology procedure(s)	Used for the professional interpretation of molecular testing when genetic sequencing or advanced analysis is performed.
`99000`	Handling and/or conveyance of a specimen for transfer from a provider to a laboratory	Administrative or handling charges associated with sending tissue for RAS testing prior to therapy.

OpenPayer